Skip to content

QUANTRX BIOMEDICAL CORPORATION: 10-Q filed 2020-11-17

What QUANTRX BIOMEDICAL CORPORATION reported in its quarterly report filed 2020-11-17 (fiscal Q3 2020): 24 published measures, 72 facts as tagged in accession 0001654954-20-012604.

This filing

Form
10-Q (quarterly report)
Filed
2020-11-17
Fiscal period
fiscal Q3 2020
Accession
0001654954-20-012604 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All QUANTRX BIOMEDICAL CORPORATION filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2020-09-3061,266USD
At 2019-12-31137,351USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2020-09-302,378,756USD
At 2019-12-312,265,672USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2020-09-30-2,317,490USD
At 2020-06-30-2,252,324USD
At 2019-12-31-2,128,321USD
At 2019-09-30-1,815,827USD
At 2019-06-30-1,716,093USD
At 2018-12-31-1,506,401USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2020-09-3061,266USD
At 2019-12-31130,351USD
At 2019-09-30154,960USD
At 2018-12-31322,024USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2020-07-01 to 2020-09-30-65,166USD92
2020-01-01 to 2020-09-30-189,169USD274
2019-07-01 to 2019-09-30-99,734USD92
2019-01-01 to 2019-09-30-309,426USD273

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2020-01-01 to 2020-09-30-69,085USD274
2019-01-01 to 2019-09-30-167,064USD273

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2020-07-01 to 2020-09-300USD92
2020-01-01 to 2020-09-300USD274
2019-07-01 to 2019-09-300USD92
2019-01-01 to 2019-09-300USD273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2020-01-01 to 2020-09-300USD274
2019-01-01 to 2019-09-300USD273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2020-01-01 to 2020-09-300USD274
2019-01-01 to 2019-09-300USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2020-09-30-52,051,421USD
At 2019-12-31-51,862,252USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2020-07-01 to 2020-09-300USD92
2020-01-01 to 2020-09-300USD274
2019-07-01 to 2019-09-300USD92
2019-01-01 to 2019-09-300USD273

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2020-07-01 to 2020-09-300USD92
2020-01-01 to 2020-09-300USD274
2019-07-01 to 2019-09-300USD92
2019-01-01 to 2019-09-300USD273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2020-07-01 to 2020-09-30-10,692USD92
2020-01-01 to 2020-09-30-51,532USD274
2019-07-01 to 2019-09-30-44,879USD92
2019-01-01 to 2019-09-30-165,718USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2020-09-3061,266USD
At 2019-12-31137,351USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2020-07-01 to 2020-09-3054,474USD92
2020-01-01 to 2020-09-30162,247USD274
2019-07-01 to 2019-09-3054,855USD92
2019-01-01 to 2019-09-30143,708USD273

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2020-09-3013,059USD
At 2019-12-3148,137USD

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2020-07-01 to 2020-09-301,908USD92
2020-01-01 to 2020-09-308,797USD274
2019-07-01 to 2019-09-3016,302USD92
2019-01-01 to 2019-09-3055,665USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2020-09-3078,696,461shares
At 2019-12-3178,696,461shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2020-09-3048,876,398USD
At 2019-12-3148,876,398USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2020-07-01 to 2020-09-30-65,166USD92
2020-01-01 to 2020-09-30-189,169USD274
2019-07-01 to 2019-09-30-99,734USD92
2019-01-01 to 2019-09-30-309,426USD273

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2020-07-01 to 2020-09-30-54,474USD92
2020-01-01 to 2020-09-30-137,637USD274
2019-07-01 to 2019-09-30-54,855USD92
2019-01-01 to 2019-09-30-143,708USD273

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2020-01-01 to 2020-09-300USD274
2019-01-01 to 2019-09-301,144USD273

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

PeriodValueUnitDays
2020-01-01 to 2020-09-300USD274
2019-01-01 to 2019-09-300USD273

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2020-01-01 to 2020-09-30-24,553USD274
2019-01-01 to 2019-09-30-4,801USD273

Inspect the source

Entity
QUANTRX BIOMEDICAL CORPORATION / CIK 0000820608
Captured
SEC response SHA-256
9ed677f1f65a020d7443764a5b8258c716645c1ae82e75ef1907f7558ecaa289

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000820608.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))